Epigenomics gets Euros1.1 million for cancer screening technology:
This article was originally published in Clinica
Executive Summary
The German Ministry for Education and Research (BMBF) has given Berlin firm Epigenomics Euros1.1m ($1.3m) to help support a three-year project to design and develop new techniques for high-throughput early cancer screening based on DNA methylation, a natural "switch" that controls gene expression. "This research will further add to the competitive advantages offered by our DNA methylation based technologies," said Kurt Berlin, the firm's chief scientific officer. Due to start in May 2004, the project aims to develop new methods for detecting cancer early that will complement and further expand Epigenomics' pipeline of methylation based products for diagnostic and pharmacodiagnostic applications, the company said.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.